Latigo Biotherapeutics (NASDAQ:LTGO) Stock Moved Down to “Sell” by Wall Street Zen

Wall Street Zen lowered shares of Latigo Biotherapeutics (NASDAQ:LTGO) from a hold rating to a sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Several other research firms also recently issued reports on LTGO. Guggenheim began coverage on shares of Latigo Biotherapeutics in a report on Tuesday, September 1st. They set a “buy” rating and a $50.00 price objective on the stock. Leerink Partners began coverage on shares of Latigo Biotherapeutics in a research report on Tuesday, September 1st. They issued an “outperform” rating and a $36.00 price objective for the company. Jefferies Financial Group started coverage on shares of Latigo Biotherapeutics in a research note on Tuesday, September 1st. They issued a “buy” rating and a $50.00 target price for the company. Finally, The Goldman Sachs Group assumed coverage on shares of Latigo Biotherapeutics in a research report on Tuesday, September 1st. They set a “buy” rating and a $73.00 target price on the stock. Four analysts have rated the stock with a Buy rating. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $52.25.

Latigo Biotherapeutics Stock Down 5.1%

Shares of NASDAQ:LTGO opened at $14.00 on Friday. The company’s 50-day simple moving average is $19.87. Latigo Biotherapeutics has a 1 year low of $13.50 and a 1 year high of $25.93. The firm has a market cap of $928.20 million and a price-to-earnings ratio of -0.26.

Latigo Biotherapeutics (NASDAQ:LTGO) last released its quarterly earnings results on Thursday, September 3rd. The company reported ($27.59) EPS for the quarter.

Insider Buying and Selling at Latigo Biotherapeutics

In other news, Director James B. Tananbaum bought 140,000 shares of Latigo Biotherapeutics stock in a transaction that occurred on Monday, August 10th. The stock was bought at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the purchase, the director directly owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. The trade was a 7.49% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Foresite Capital Management V, bought 140,000 shares of Latigo Biotherapeutics stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the purchase, the insider directly owned 2,008,024 shares in the company, valued at $36,144,432. The trade was a 7.49% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Latigo Biotherapeutics Company Profile

Latigo Biotherapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing non-opioid treatments for acute and chronic pain. The company’s research centers on selectively targeting Nav1.8, a sodium channel involved in the transmission of pain signals, with the goal of creating therapies that may provide pain relief without the risks associated with opioid medicines.

Latigo’s pipeline includes small-molecule Nav1.8 inhibitors, including LTG-001, an investigational candidate being evaluated for pain-related conditions.